Grants Still Most Expensive in the United States
TTC
Many factors affect a sponsor's decision to pick a region in which to conduct a clinical trial. Clinical grant expenditures represent a significant portion of later phase clinical trial budgets. Therefore, the relative cost per patient can play a large role in which region to select.
The cost per patient in Asia and Latin American is increasing much faster than in the United States.
TTC maintains annual current global data on the relative costs of clinical grants around the world in the GrantPlan® database. The database contains the clinical grants for sponsor companies and CROs that together conduct over 76% of all commercial clinical trials.
The current update demonstrates that, after controlling for study design, the United States remains the most expensive region for clinical grants by a large margin. Latin America and Asia exhibit less expensive costs per patient with 55% and 44% of the United States' 2009 cost per patient, respectively.
The cost per patient in these newer geographies, however, is growing more rapidly than in more established regions. The United States has been averaging 5.5% annual increases from 2009 through 2011, while grant costs in Asia and Latin America are growing at two to three times those rates.
—TTC - for more information, please contact help@ttc-llc.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
